343 related articles for article (PubMed ID: 27913578)
1. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
2. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
[TBL] [Abstract][Full Text] [Related]
3. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
[TBL] [Abstract][Full Text] [Related]
4. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
5. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Ercan D; Choi HG; Yun CH; Capelletti M; Xie T; Eck MJ; Gray NS; Jänne PA
Clin Cancer Res; 2015 Sep; 21(17):3913-23. PubMed ID: 25948633
[TBL] [Abstract][Full Text] [Related]
6. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
[TBL] [Abstract][Full Text] [Related]
8. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
[TBL] [Abstract][Full Text] [Related]
9. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
11. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
12. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Niederst MJ; Hu H; Mulvey HE; Lockerman EL; Garcia AR; Piotrowska Z; Sequist LV; Engelman JA
Clin Cancer Res; 2015 Sep; 21(17):3924-33. PubMed ID: 25964297
[TBL] [Abstract][Full Text] [Related]
13. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
14. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.
Nakamura T; Nakashima C; Komiya K; Kitera K; Hirai M; Kimura S; Aragane N
PLoS One; 2018; 13(12):e0209384. PubMed ID: 30550608
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Lee C; Kim M; Kim DW; Kim TM; Kim S; Im SW; Jeon YK; Keam B; Ku JL; Heo DS
Cancer Res Treat; 2022 Jan; 54(1):140-149. PubMed ID: 33940786
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Janjigian YY; Smit EF; Groen HJ; Horn L; Gettinger S; Camidge DR; Riely GJ; Wang B; Fu Y; Chand VK; Miller VA; Pao W
Cancer Discov; 2014 Sep; 4(9):1036-45. PubMed ID: 25074459
[TBL] [Abstract][Full Text] [Related]
18. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
[TBL] [Abstract][Full Text] [Related]
20. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
